salmeterol xinafoate has been researched along with Lymphopenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourbeau, J; Christodoulopoulos, P; Hamid, Q; Maltais, F; Olivenstein, R; Yamauchi, Y | 1 |
| Ind, PW; Johnston, SR; Seale, J; Spring, J | 1 |
2 trial(s) available for salmeterol xinafoate and Lymphopenia
| Article | Year |
|---|---|
Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.
Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Bronchitis; Bronchodilator Agents; CD8-Positive T-Lymphocytes; Double-Blind Method; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Humans; Immunohistochemistry; Lymphopenia; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Vital Capacity | 2007 |
Failure of salmeterol to inhibit circulating white cell responses and bronchoconstriction induced by platelet activating factor.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Bronchoconstriction; Double-Blind Method; Female; Humans; Inflammation; Leukocyte Count; Lymphocytes; Lymphopenia; Male; Neutrophils; Platelet Activating Factor; Salmeterol Xinafoate | 1992 |